EGFR Mutations Detected in Plasma Are Associated with Patient Outcomes in Erlotinib Plus Docetaxel-Treated Non-small Cell Lung Cancer-Reference-Cited by-同舟云学术

EGFR Mutations Detected in Plasma Are Associated with Patient Outcomes in Erlotinib Plus Docetaxel-Treated Non-small Cell Lung Cancer

Published:2009-12 Issue:12 Volume:4 Page:1466-1472
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Mack Philip C.,Holland William S.,Burich Rebekah A.,Sangha Randeep,Solis Leslie J.,Li Yueju,Beckett Laurel A.,Lara Primo N.,Davies Angela M.,Gandara David R.

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference36 articles.

1. Cancer statistics, 2007;Jemal;CA Cancer J Clin,2007

2. Erlotinib in lung cancer-molecular and clinical predictors of outcome;Tsao;N Engl J Med,2005

3. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer);Thatcher;Lancet,2005

4. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial—INTACT 1;Giaccone;J Clin Oncol,2004

5. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial–INTACT 2;Herbst;J Clin Oncol,2004

Cited by 60 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Detection of KRAS mutation using plasma samples in non-small-cell lung cancer: a systematic review and meta-analysis;Frontiers in Oncology;2023-07-06

2. The evolving role of liquid biopsy in lung cancer;Lung Cancer;2022-10

3. Randomized phase III study of docetaxel versus docetaxel plus intercalated erlotinib in patients with relapsed non-squamous non-small cell lung carcinoma;Lung Cancer;2021-10

4. Impact of detecting plasma EGFR mutations with ultrasensitive liquid biopsy in outcomes of NSCLC patients treated with first- or second-generation EGFR-TKIs;Cancer Biomarkers;2021-09-24

5. Effect of CTCs and INHBA level on the effect and prognosis of different treatment methods for patients with early breast cancer;EUR REV MED PHARMACO;2020